A Study Evaluating the Efficacy and Safety of Recombinant Human Truncated Plasmin Injection (JZB32) in Patients With Vitreomacular Traction

November 1, 2026 updated by: Jiangsu Jingze Biopharmaceutical Co., Ltd.

A Randomized, Double-Blind, Multicenter, Sham Injection-Controlled, Parallel-Group Phase II Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Truncated Plasmin Injection (JZB32) in Patients With Vitreomacular Traction

This study aims to evaluate the efficacy of JZB32 in patients with vitreomacular traction (VMT). Based on a randomized, double-blind, multicenter, sham injection-controlled, parallel-group design, the proportion of study eyes achieving VMT resolution assessed by optical coherence tomography (OCT) at Day 28 will be compared between the JZB32 group and the sham injection group.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Currently, there are no effective pharmacological treatments available for patients with vitreomacular traction (VMT). Management options are primarily limited to "watchful waiting" and pars plana vitrectomy (PPV), which carries potential complications. This study will evaluate the efficacy of JZB32 in patients with VMT by comparing the rate of OCT-assessed VMT resolution in study eyes at Day 28 (D28) between JZB32 and sham injection.

Study Type

Interventional

Enrollment (Estimated)

48

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Anhui
      • Hefei, Anhui, China
        • Recruiting
        • The Second Hospital of Anhui Medical University
    • Beijing Municipality
      • Beijing, Beijing Municipality, China
        • Recruiting
        • Beijing Tongren Hospital, Capital Medical University
    • Gansu
      • Lanzhou, Gansu, China
        • Recruiting
        • The Second Hospital of Lanzhou University
    • Guangdong
      • Shenzhen, Guangdong, China
        • Recruiting
        • Shenzhen Eye Hospital
    • Guangxi
      • Nanning, Guangxi, China
        • Recruiting
        • The People's Hospital of Guangxi Zhuang Autonomous Region
    • Hebei
      • Shijiazhuang, Hebei, China
        • Recruiting
        • Shijiazhuang People's Hospital
    • Hubei
      • Wuhan, Hubei, China
        • Recruiting
        • Renmin Hospital of Wuhan University
      • Wuhan, Hubei, China
        • Recruiting
        • Central Theater Command General Hospital of the Chinese People's Liberation Army
    • Jilin
      • Changchun, Jilin, China
        • Recruiting
        • The Second Hospital of Jilin University
    • Shaanxi
      • Xi'an, Shaanxi, China
        • Recruiting
        • The First Hospital of Xi'an
    • Shanxi
      • Taiyuan, Shanxi, China
        • Recruiting
        • Shanxi Eye Hospital, China
    • Sichuan
      • Chengdu, Sichuan, China
        • Recruiting
        • West China Hospital, Sichuan University
    • Zhejiang
      • Hangzhou, Zhejiang, China
        • Recruiting
        • Zhejiang Provincial People's Hospital
      • Hangzhou, Zhejiang, China
        • Recruiting
        • The Second Affiliated Hospital, Zhejiang University School of Medicine (SAHZU)
      • Wenzhou, Zhejiang, China
        • Recruiting
        • Eye Hospital, Wenzhou Medical University (Zhejiang Eye Hospital)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Aged≥18 years at the time of signing the informed consent form, regardless of gender.
  2. Vitreomacular traction (VMT) in the study eye confirmed by optical coherence tomography (OCT), defined as attachment of the posterior vitreous cortex to the retinal surface within a 3 mm radius of the fovea, resulting in abnormalities such as foveal deformation, elevation, or alterations in retinal morphology and structure.
  3. Best-Corrected Visual Acuity (BCVA) in the study eye of ≤ 20/25 (≤ 83 letters) and in the non-study eye of ≥ 20/400 (≥19 letters), measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.
  4. Capable of understanding and willing to participate in the study, with informed consent signed by the participant or their legally authorized representative, and willing to comply with the treatment schedule and attend all scheduled follow-up visits as required by the protocol.

Exclusion Criteria:

  1. Presence of an epiretinal membrane (ERM) coinciding with vitreomacular traction (VMT) in the study eye.

  2. Diameter of the macular hole > 400 μm in the study eye (applicable if a full-thickness macular hole is present in the study eye).

  3. Axial length > 28 mm in the study eye.

  4. Presence of other ocular conditions in the study eye that may confound the interpretation of study results or require urgent treatment, including but not limited to: proliferative diabetic retinopathy (PDR); central retinal vein occlusion (CRVO); branch retinal vein occlusion (BRVO); wet age-related macular degeneration (wAMD); choroidal neovascularization (CNV); uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite anti-glaucoma treatment), or a cup-to-disc ratio > 0.8 in the study eye caused by glaucoma.

  5. Presence of other ocular media opacities in the study eye, such as leukoma, cataract, vitreous opacity/hemorrhage, or posterior iris synechiae, which, in the opinion of the investigator, would interfere with OCT, BCVA, fundus examination, or intravitreal injection procedures.

  6. Presence of pseudoexfoliation syndrome, Marfan syndrome, aphakia, or any other condition in the study eye judged by the investigator to cause zonular instability.

  7. History of retinal detachment in the study eye.

  8. History of non-pharmacological therapies in the study eye: prior vitrectomy, macular laser photocoagulation, fundus surgery, ab externo ocular surgery, or anti-glaucoma surgery; cataract surgery within 90 days prior to injection; intravitreal injection or laser procedures (e.g., retinal photocoagulation, laser iridotomy, posterior capsulotomy) within 30 days prior to injection; or ocular surface surgery (e.g., entropion repair, pterygium excision) within 30 days prior to injection.

  9. Active or suspected ocular or periocular infection in either eye (e.g., blepharitis, infectious conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis).

  10. Uncontrolled psychiatric disorders, central nervous system diseases, Down syndrome, asthma, severe cardiopulmonary dysfunction, severe hepatic or renal impairment, malignant tumors, hypertension, or diabetes mellitus at screening (unless judged eligible by the investigator).

  11. Positive screening for Hepatitis B (defined as HBsAg positive and HBV-DNA ≥ 2000 IU/mL), Hepatitis C (defined as anti-HCV positive and HCV-RNA positive), Human Immunodeficiency Virus (HIV) antibodies, or Treponema pallidum (Anti-TP) specific antibodies.

  12. Use of plasmin or plasminogen activator drugs (e.g., alteplase) systemically or topically in the eye within 30 days prior to injection, or potential need for such treatment during the study period.

  13. Current use or anticipated need during the study period of medications known to cause lens, retinal, or optic nerve toxicity (e.g., deferoxamine, chloroquine, hydroxychloroquine, tamoxifen, phenothiazines, or ethambutol).

  14. Known hypersensitivity or contraindications to the investigational drug or any of its components, or to required study medications (e.g., anesthetics, mydriatics, antibiotics).

  15. Participation in any drug (excluding vitamins and minerals) or medical device clinical trial within 30 days prior to injection and receipt of study drug or device. If 5 half-lives of the investigational drug exceeds 30 days, 5 half-lives shall apply.

  16. Unwillingness or failure to use effective contraception during the study period;

    Note: The following conditions are not grounds for exclusion:

    1. Natural menopause defined as amenorrhea for ≥12 months;

    2. Bilateral oophorectomy, with or without hysterectomy, performed ≥6 weeks prior;

    3. Use of one or more of the following acceptable methods of contraception:

      • Sterilization;
      • Hormonal contraception;
      • Intrauterine device (IUD);
      • Double-barrier methods;

    4. Ability to maintain reliable contraception throughout the study period.

  17. Pregnant (defined as a positive urine or serum pregnancy test) or lactating females.

  18. Any other conditions or factors that, in the opinion of the investigator, render the participant unsuitable for the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: JZB32 Group

Recombinant Human Truncated Plasmin Injection (JZB32)
Drug: Recombinant Human Truncated Plasmin Injection (JZB32)

Single intravitreal injection of JZB32
Sham Comparator: Sham Injection Group

Sham injection control
Other: Sham injection

Single sham intravitreal injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of study eyes with resolution of vitreomacular traction (VMT) assessed by OCT
Time Frame: Day 28

An efficacy outcome measure evaluating the rate of vitreomacular traction (VMT) resolution in the study eye using optical coherence tomography (OCT) at Day 28.
Day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jiangsu Jingze Biopharmaceutical Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 8, 2026

Primary Completion (Estimated)

December 28, 2027

Study Completion (Estimated)

May 30, 2028

Study Registration Dates

First Submitted

October 27, 2026

First Submitted That Met QC Criteria

October 27, 2026

First Posted (Actual)

November 2, 2026

Study Record Updates

Last Update Posted (Actual)

November 4, 2026

Last Update Submitted That Met QC Criteria

November 1, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • JZB32VMT201

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe